Search

Your search keyword '"Robesti D."' showing total 359 results

Search Constraints

Start Over You searched for: Author "Robesti D." Remove constraint Author: "Robesti D."
359 results on '"Robesti D."'

Search Results

1. The impact of centralized uropathology review in the management of bladder cancer patients at the time of transurethral resection of the bladder

2. PSA doubling time thresholds in predicting clinical recurrence after biochemical recurrence in surgically treated prostate cancer patients. The Impact of nodal status and adjuvant radiotherapy

3. Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series

4. Age-dependent effect of early salvage radiotherapy for biochemical recurrence in prostate cancer patients treated with radical prostatectomy

5. The significant added value of concomitant systematic prostate biopsies in addition to targeted sampling in patients with previous negative biopsies. Implications for accurate staging predictions from a large multi-institutional series

6. PSMA radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Updated results of a planned interim analysis of a prospective phase 2 study

7. Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG

8. External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET

9. Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET

10. Long-term oncological outcomes of surgically managed very high-risk prostate cancer patients according to the STAMPEDE trial definition: Implications for the selection of candidates for clinical trials

11. Validation of the EAU risk groups for radical prostatectomy prostate cancer patients who experienced biochemical recurrence restaged with PSMA PET imaging and development of a novel tool

13. Four dimension analysis of heat generation during Ho:YAG and thulium fiber laser activation: An in vitro thermographic study

14. A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series

15. The role of artificial intelligence for the detection of clinically significant prostate cancer at multiparametric magnetic resonance imaging

16. Optimizing the number of systematic cores during MRI target biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial

17. Effect of Metastasis Directed Therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series

18. The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, singe Institution series

19. Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

20. How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series

21. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study

22. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification

23. Oncologic outcomes of patients with incidental prostate cancer: Can we rely on multiparametric mri to exclude aggressive prostate cancer?

24. Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?

25. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series

26. Does a positive multi-parametric MRI always warrant prostate biopsy? the importance of integrating clinical and imaging data based on a large, multi-institutional series

27. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics

28. 99M-technetium-psma radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing radical prostatectomy and extended pelvic lymph node dissection: a phase 2 prospective, single-institution study

29. The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to the type preoperative staging. a comparison between 68ga-PSMA-PET versus conventional imaging in a large, multi-institutional study

30. Are extended pelvic lymph node dissection-related complications still an issue in contemporary patients treated with robot-assisted radical prostatectomy? a prospective assessment using a standardized collection system

31. When is neoadjuvant androgen deprivation therapy beneficial for highly aggressive prostate cancer before radical prostatectomy? implications for multi-modal tailored approaches and trials design

32. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series

33. Can low risk disease outside the index lesion be left untreated in men suitable for focal therapy? development of novel criteria to identify potential candidates for focal therapy among patients with intermediate risk prostate cancer and positive multi-parametric MRI

34. Reliability of 68Ga-PSMA PET/CT in assessing real nodal burden in men with cN1 disease: clinical implications for patient counselling and multi-modal treatments

35. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy

36. The impact of frailty status on surgical outcomes after robot-assisted radical prostatectomy - a prospective assessment using a standardized collection system for perioperative outcomes

37. Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection

38. The impact of histological variants on the performance characteristics of 68Ga-PSMA PET/CT in the primary and recurrent setting

39. Assessing the role of frailty status on oncologic and functional outcomes in patients treated with robot-assisted radical prostatectomy for localized prostate cancer

40. Detection of clinically significant prostate cancer in mpMRI visible lesions: size matters. Results from a large, two-institutional series

41. Histological variants of prostate cancer are under-reported in prostate biopsies assessed outside tertiary referral centers. a plea for biopsy review for optimal patient management

42. Delaying post-operative radiation therapy after radical prostatectomy is associated with increased functional outcomes: results from a large single, referral center series

43. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology

45. Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy

46. Radikale Prostatektomie (RP) oder Radiotherapie (RT) beim metastasierten, hormonnaiven Prostatakarzinom (PCA) mit geringer Metastasenlast: Ein indirekter Vergleich mit der STAMPEDE Studie, Arm H

47. Does centralized revision of prostate biopsy impact on active surveillance outcomes? Results from a single, high-volume institution series

48. The key role of concomitant androgen-deprivation therapy on the efficacy of imaging guided treatments in men with biochemical recurrent prostate cancer after radical prostatectomy and 68Ga-PSMA PET/CT scan

49. When is neoadjuvant androgen deprivation therapy beneficial for highly aggressive prostate cancer before radical prostatectomy? Implications for multi-modal tailored approaches and trials design

50. Are extended pelvic lymph node dissection-related complications still an issue in contemporary patients treated with robot-assisted radical prostatectomy? A prospective assessment using a standardized collection system

Catalog

Books, media, physical & digital resources